^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Excerpt:
Have documentation of V600-activating BRAF mutation status or consent to BRAF V600 mutation testing during the screening period.
Trial ID: